Last Published 07.01.2026 Effective Date: 07.01.2026 This policy addresses the use of interleukin-5 (IL-5) antagonists, including Cinqair (reslizumab), Fasenra (benralizumab), and Nucala (mepolizumab)
Having that understanding will allow healthcare providers to better guide how we manage and monitor patients. Advertisement Sign up for our Health Essentials emails for expert guidance on nutrition, fitness, sleep, skin care and more
Under this plan, Medicare recipients are expected to be covered for GLP-1s, with a $50 monthly cap on patient out-of-pocket spending
There, the right answer is rarely an appeal
Glucagon-like Peptide-1 Receptor Signalling Selectively Regulates Murine Lymphocyte Proliferation and Maintenance of Peripheral Regulatory T Cells
Boosting metabolic hormones: Preclinical data suggest it increases GLP-1 (un-hunger hormone) and supports blood sugar balance